Latest news : Valeo Pharma Inc.

25-02-04	Xediton Pharmaceuticals Inc. completed the acquisition of Valeo Pharma Inc. (OTCPK:VPHI.F).	CI
25-01-16	Xediton Pharmaceuticals Inc. entered into a definitive agreement to acquire Valeo Pharma Inc. (OTCPK:VPHI.F).	CI
24-01-28	Valeo Pharma Inc. Auditor Raises 'Going Concern' Doubt	CI

More news

Press Releases: Valeo Pharma Inc.

25-02-06	Valeo Pharma announces the closing of a share purchase agreement with Xediton Pharmaceuticals Inc.	AQ
22-01-05	VALEO PHARMA'S HESPERCO™ NOW AVAILABLE AT LOBLAWS, HESPERIDIN COVID-19 CLINICAL TRIAL RESULTS SUBMITTED FOR PUBLICATION	PR
21-11-03	Valeo Pharma Obtains Public Reimbursement For Enerzair® Breezhaler® and Atectura® Breezhaler® In Alberta	PR
21-10-13	Valeo Pharma : C O R R E C T I O N from Source -- Valeo Pharma inc./	PR
21-10-05	Valeo Pharma : Completes Negotiations with Pan-Canadian Pharmaceutical Alliance for Enerzair® Breezhaler® and Atectura® Breezhaler®	PR

More press releases

Managers and Directors: Valeo Pharma Inc.

Manager	Title	Age	Since
Pascal Tougas DFI	Director of Finance/CFO	-	2023-11-19
Nelly Komari CTO	Chief Tech/Sci/R&D Officer	-	2021-05-31
Frédéric Dumais IRC	Investor Relations Contact	-	2019-05-31

Director	Title	Age	Since
Steven Saviuk CHM	Chairman	67	2024-08-05
Richard MacKay CHM	Chairman	91	2018-07-24
Marc Léger BRD	Director/Board Member	67	2022-04-26

More insiders

Valeo Pharma Inc. is a Canadian pharmaceutical company. The Company acquires, or in-licenses branded pharmaceuticals and hospital specialty products for sale in Canada. The Company is engaged in the commercialization of prescription products in Canada with a focus on respiratory/allergy, ophthalmology and hospital specialty products. Its respiratory/allergy products include Enerzair Breezhaler, Atectura Breezhaler and Allerject. The ophthalmology products include Xiidra and Simbrinza. Its specialty products include Redesca, Onstryv, M-Eslon, Yondelis and Ametop Gel 4%. The Company's wholly owned subsidiary is VPI Pharmaceuticals Inc.

Employees

Sector

Pharmaceuticals

More about the company

Income Statement and Estimates

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Market Closed - OTC Markets Other stock markets 14:51:36 2026-02-11 EST			5-day change	1st Jan Change
0.000001 ^USD	-99.00%		-.--%	-99.00%

Market Cap	6.24M 4.4M 3.86M 3.56M 3.29M 421M 6.36M 42.82M 16.64M 206M 16.52M 16.15M 715M	P/E 2022	-2.09x	P/E 2023	-0.45x
Enterprise Value	64.5M 45.47M 39.89M 36.82M 34.03M 4.35B 65.79M 443M 172M 2.13B 171M 167M 7.4B	EV / Sales 2022	3.37x	EV / Sales 2023	1.35x
Free-Float	52.66%	Yield 2022 *	-	Yield 2023	-

Current year	0		0
1 year	0		0
3 years	0		0.4
5 years	0		0.84
10 years	0		1.4

Date	Insider	Type	Main position	% Market Cap.
24-11-10	Frédéric Dumais	Other	Investor Relations Manager	0%
24-11-10	Frédéric Dumais	Other	Investor Relations Manager	0%
24-11-10	Frédéric Dumais	Other	Investor Relations Manager	0%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
VALEO PHARMA INC.	-99.00%	-.--%	-	-	98
ELI LILLY AND COMPANY	-1.60%	+2.02%	+56.34%	+168.94%	1,084B
JOHNSON & JOHNSON	-1.44%	+3.71%	+69.07%	+65.40%	634B
ABBVIE INC.	-0.75%	+0.67%	+33.18%	+86.52%	447B
ROCHE HOLDING AG	-1.35%	+1.86%	+29.96%	+26.28%	330B
ASTRAZENECA PLC	-0.86%	+2.79%	+37.72%	+40.85%	295B
NOVARTIS AG	-0.71%	+0.72%	+28.85%	+48.27%	285B
NOVO NORDISK A/S	-1.31%	-0.26%	-28.18%	-39.82%	218B
AMGEN INC.	-0.03%	+1.84%	+23.90%	+68.30%	199B
GILEAD SCIENCES, INC.	-0.40%	+7.82%	+22.29%	+82.50%	169B
Average	-10.74%	+2.27%	+30.35%	+60.81%	365.99B
Weighted average by Cap.	-1.16%	+2.48%	+41.34%	+86.49%

Valeo Pharma Inc. Stock

Stocks

VPHIF

CA91915B1085

Pharmaceuticals

Valuation: Valeo Pharma Inc.

Chart: Valeo Pharma Inc.

Latest news : Valeo Pharma Inc.

Press Releases: Valeo Pharma Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Valeo Pharma Inc.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Income Statement and Estimates

Quarterly revenue - Rate of surprise

	2022	2023
Net sales	27.74M 19.56M 17.16M 15.84M 14.64M 1.87B 28.3M 190M 73.99M 917M 73.46M 71.85M 3.18B	53.91M 38.01M 33.34M 30.78M 28.44M 3.64B 54.99M 370M 144M 1.78B 143M 140M 6.18B
Net income	-25.75M -18.15M -15.92M -14.7M -13.58M -1.74B -26.26M -177M -68.66M -851M -68.17M -66.67M -2.95B	-27.81M -19.61M -17.2M -15.88M -14.67M -1.88B -28.36M -191M -74.16M -919M -73.63M -72.01M -3.19B
Net Debt	38.94M 27.46M 24.08M 22.23M 20.54M 2.63B 39.72M 267M 104M 1.29B 103M 101M 4.47B	58.26M 41.08M 36.03M 33.26M 30.74M 3.93B 59.43M 400M 155M 1.92B 154M 151M 6.68B